| |
| |
|
| Insider
Information: |
Glickman Mark A |
| Relationship: |
Director |
| City: |
Skillman |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
370,201 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$63,540 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
370,201 |
|
|
| Total
Value |
$63,540 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -25.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Oscient Pharmaceuticals Corp |
OSCIQ |
Officer |
2008-07-28 |
26,157 |
2008-07-28 |
0 |
Premium* |
|
|
POZEN Inc |
POZN |
Chief Commercial Officer |
2015-06-22 |
29,137 |
2015-06-22 |
0 |
Premium* |
|
|
Aralez Pharmaceuticals Inc. |
ARLZ |
Chief Commercial Officer |
2018-03-19 |
250,188 |
2016-02-05 |
0 |
Premium* |
|
|
Esperion Therapeutics, Inc. |
ESPR |
Chief Commercial Officer |
2020-01-02 |
25,925 |
2020-01-02 |
0 |
Premium* |
|
|
Therapeuticsmd Inc |
TXMD |
Co-Chief Executive Off... |
2022-12-06 |
1,294 |
2022-12-06 |
0 |
Premium* |
|
|
NeuroBo Pharmaceuticals Inc |
NRBO |
Director |
2023-07-27 |
37,500 |
2023-07-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
14 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NRBO |
NeuroBo Pharmaceuticals I... |
Director |
– • – |
2023-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
0 |
- |
|
| TXMD |
Therapeuticsmd Inc |
Co-Chief Executive Officer |
• – – |
2022-12-06 |
4 |
S |
$4.92 |
$2,165 |
D/D |
(440) |
1,294 |
0 |
% |
|
| TXMD |
Therapeuticsmd Inc |
Co-Chief Executive Officer |
• – – |
2022-12-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,734 |
1,734 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Chief Commercial Officer |
• – – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,925 |
25,925 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Chief Commercial Officer |
• – – |
2018-03-19 |
4 |
AS |
$1.70 |
$9,733 |
D/D |
(5,725) |
250,188 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Chief Commercial Officer |
• – – |
2017-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
80,163 |
255,913 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Chief Commercial Officer |
• – – |
2016-06-22 |
4 |
D |
$3.34 |
$36,082 |
D/D |
(10,803) |
175,750 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Chief Commercial Officer |
• – – |
2016-05-16 |
4 |
B |
$3.68 |
$92,050 |
D/D |
25,000 |
186,553 |
2.74 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Chief Commercial officer |
• – – |
2016-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
45,553 |
161,553 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Chief Commercial Officer |
• – – |
2016-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
86,863 |
116,000 |
0 |
- |
|
| ARLZ |
Aralez Pharmaceuticals In... |
Chief Commercial Officer |
• – – |
2016-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
29,137 |
29,137 |
0 |
- |
|
| POZN |
POZEN Inc |
Chief Commercial Officer |
• – – |
2015-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
29,137 |
29,137 |
0 |
- |
|
| OSCIQ |
Oscient Pharmaceuticals C... |
SVP, Sales & MarketingOfficer |
• – – |
2008-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,157 |
|
- |
|
| OSCIQ |
Oscient Pharmaceuticals C... |
SVP, Sales & Marketing |
• – – |
2008-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
36,157 |
0 |
- |
|
14 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
